Page last updated: 2024-12-08

decursin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

decursin: activates protein kinase C; isolated from the root of Angelica gigas; RN given for (S)-isomer; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

FloraRankFlora DefinitionFamilyFamily Definition
AngelicagenusA plant genus of the family Apiaceae.[MeSH]ApiaceaeA large plant family in the order Apiales, also known as Umbelliferae. Most are aromatic herbs with alternate, feather-divided leaves that are sheathed at the base. The flowers often form a conspicuous flat-topped umbel. Each small individual flower is usually bisexual, with five sepals, five petals, and an enlarged disk at the base of the style. The fruits are ridged and are composed of two parts that split open at maturity.[MeSH]

Cross-References

ID SourceID
PubMed CID442126
CHEMBL ID481658
CHEBI ID4353
SCHEMBL ID14511556
MeSH IDM0265563

Synonyms (37)

Synonym
(s)-7,8-dihydro-8,8-dimethyl-2-oxo-2h,6h-benzo(1,2-b:5,4-b')dipyran-7-yl 3-methyl-2-butenoate
unii-e95rto3yqr
2-butenoic acid, 3-methyl-, 7,8-dihydro-8,8-dimethyl-2-oxo-2h,6h-benzo(1,2-b:5,4-b')dipyran-7-yl ester, (s)-
e95rto3yqr ,
decursin
C09258
5928-25-6
[(3s)-2,2-dimethyl-8-oxo-3,4-dihydropyrano[3,2-g]chromen-3-yl] 3-methylbut-2-enoate
AC1L9CAH ,
CHEMBL481658 ,
chebi:4353 ,
(s)-(+)-decursin
2-butenoic acid, 3-methyl-, (7s)-7,8-dihydro-8,8-dimethyl-2-oxo-2h,6h-pyrano(3,2-g)-1-benzopyran-7-yl ester
bdbm50361396
S9264
(+)-decursin
crotonic acid, 3-methyl-, ester with 7,8-dihydro-7-hydroxy-8,8-dimethyl-2h,6h-benzo(1,2-b:5,4-b')dipyran-2-one, (+)-
decursin [inci]
SCHEMBL14511556
AKOS025149080
AC-35119
ambap5928-25-6
(s)-2,2-dimethyl-8-oxo-2,3,4,8-tetrahydropyrano[3,2-g]chromen-3-yl 3-methylbut-2-enoate
mfcd00272154
Q27106347
BCP10293
ZB1887
CS-0014824
HY-18981
decursin ((+)-decursin)
HMS3887A11
DTXSID90974706
8,8-dimethyl-2-oxo-7,8-dihydro-2h,6h-benzo[1,2-b:5,4-b']dipyran-7-yl 3-methylbut-2-enoate
CCG-267790
3-methyl-2-butenoic acid, (7s)-7,8-dihydro-8,8-dimethyl-2-oxo-2h,6h-pyrano[3,2-g]-1-benzopyran-7-yl ester
AS-79221
2-butenoic acid, 3-methyl-, (7s)-7,8-dihydro-8,8-dimethyl-2-oxo-2h,6h-benzo[1,2-b:5,4-b']dipyran-7-yl ester

Research Excerpts

Overview

Decursinol is a major coumarin derived from the roots of Angelica gigas. It has various pharmacological effects against inflammation, angiogenesis, nociceptive pain and Alzheimer's disease. Decursin is known to induce apoptosis of metastatic prostatic cancer cells.

ExcerptReferenceRelevance
"Decursin is a coumarin with a range of pharmacological effects."( Decursin inhibits the oxidation of low-density lipoprotein and protects human aortic endothelial cells against oxidative damage.
Ji, B; Wang, X; Yang, Y; Yu, J, 2020
)
2.72
"Decursin is an active compound extracted from the roots of Angelica gigas and has been shown to have potent anti-cancer and anti-angiogenic activities."( Decursin promotes HIF-1α proteasomal degradation and immune responses in hypoxic tumour microenvironment.
Ge, Y; Jang, H; Jeong, JH; Lee, YM; Yoon, SH, 2020
)
2.72
"Decursin is a novel therapeutic that targets the vascular endothelial growth factor (VEGF) receptor (VEGFR) with putative anti-proliferative and anti-angiogenic activities."( Decursin inhibited proliferation and angiogenesis of endothelial cells to suppress diabetic retinopathy via VEGFR2.
Hu, Y; Li, X; Li, Y; Meng, H; Sun, Q; Yang, K; Yang, Y; Zeng, Y; Zhang, Y, 2013
)
2.55
"Decursinol is a major coumarin derived from the roots of Angelica gigas and has various pharmacological effects against inflammation, angiogenesis, nociceptive pain and Alzheimer's disease. "( Pharmacokinetic characterization of decursinol derived from Angelica gigas Nakai in rats.
Ahn, SH; Bae, MA; Chae, JW; Choi, EJ; Kwon, KI; Lee, BH; Lee, KR; Song, JS, 2011
)
2.09
"Decursin is a major biological active component of Angelicagigas Nakai and is known to induce apoptosis of metastatic prostatic cancer cells. "( Decursin from Angelicagigas Nakai induces apoptosis in RC-58T/h/SA#4 primary human prostate cancer cells via a mitochondria-related caspase pathway.
Choi, SR; Jeong, IY; Kim, JY; Lee, JH; Lee, MK; Park, KW; Seo, KI; Shim, KH, 2011
)
3.25

Effects

ExcerptReferenceRelevance
"Decursin has been demonstrated to exhibit potent anti-cancer activity both in vitro and in vivo."( Decursin and decursinol inhibit VEGF-induced angiogenesis by blocking the activation of extracellular signal-regulated kinase and c-Jun N-terminal kinase.
Chung, WY; Kang, SS; Kim, MJ; Kim, YC; Kim, YS; Lee, SK; Park, KK; Son, JA; Son, SH, 2009
)
2.52

Treatment

Decursin treatment significantly reduced the ratio of liver/body weight, α-SMA activation, and type I collagen overexpression in CCl4 treated mice liver. The decursin-treated KA-injected group showed significantly decreased behavioral seizure activity and remarkably attenuated intense and high-frequency seizure discharges in the parietal cortex.

ExcerptReferenceRelevance
"Decursin treatment significantly reduced the ratio of liver/body weight, α-SMA activation, and type I collagen overexpression in CCl4 treated mice liver. "( Decursin attenuates hepatic fibrogenesis through interrupting TGF-beta-mediated NAD(P)H oxidase activation and Smad signaling in vivo and in vitro.
Choi, YJ; Chung, CH; Jeong, SI; Kim, DH; Kim, J; Kim, SJ; Kim, SY; Yu, KY, 2014
)
3.29
"The decursin-treated KA-injected group showed significantly decreased behavioral seizure activity and remarkably attenuated intense and high-frequency seizure discharges in the parietal cortex for 2 h compared with the group treated only with KA."( Decursin attenuates kainic acid-induced seizures in mice.
Han, H; Jang, T; Jeong, JW; Kang, JS; Kim, IH; Lee, GW; Lee, JK, 2014
)
2.33
"Decursin treatment resulted in the inhibition of adipocyte differentiation and the expression of fatty acid synthase."( Decursin, an active compound isolated from Angelica gigas, inhibits fat accumulation, reduces adipocytokine secretion and improves glucose tolerance in mice fed a high-fat diet.
Cha, MR; Hur, HJ; Hwang, JT; Kim, HJ; Kim, MS; Kim, SH; Kim, YS; Kwon, DY; Park, JH; Ryu, SY; Sung, MJ; Yang, HJ, 2012
)
2.54
"Treatment of decursin markedly proved the generation of reactive oxygen species, NAD(P)H oxidase (NOX) protein (1, 2, and 4) upregulation, NOX activity, and superoxide anion production in HSCs by TGF-β1."( Decursin attenuates hepatic fibrogenesis through interrupting TGF-beta-mediated NAD(P)H oxidase activation and Smad signaling in vivo and in vitro.
Choi, YJ; Chung, CH; Jeong, SI; Kim, DH; Kim, J; Kim, SJ; Kim, SY; Yu, KY, 2014
)
2.2

Toxicity

ExcerptReferenceRelevance
" Ether decursin exhibited a toxic effect after being applied to mouse (NIH 3T3, EC₅₀: 57."( Physicochemical characterization and toxicity of decursin and their derivatives from Angelica gigas.
Baek, IH; Chae, JW; Cho, SK; Kwon, KI; Mahat, B; Song, GY; Song, JS, 2012
)
1.09

Pharmacokinetics

The clearance, elimination rate constant (K(el) of theophylline was significantly decreased. The area under concentration-time curve (AUC), C(max), half-life was increased in decursin (25mg/kg) pretreatment.

ExcerptReferenceRelevance
" The elimination half-life (t1/2) of theophylline was increased by 20%."( Effect of decursinol angelate on the pharmacokinetics of theophylline and its metabolites in rats.
An, JH; Chae, JW; Kang, W; Kwon, KI; Ma, Jy, 2012
)
0.78
"The results indicated that the clearance, elimination rate constant (K(el)) of theophylline was significantly decreased and area under concentration-time curve (AUC), C(max), half-life was increased in decursin (25mg/kg) pretreatment when theophylline (10mg/kg) was given."( Effect of decursin on the pharmacokinetics of theophylline and its metabolites in rats.
Baek, IH; Chae, JW; Kwon, KI, 2012
)
0.97
" We tested the anti-inflammatory effect of JHL45 by in vitro screening, characterized its in vitro pharmacokinetic (PK) properties."( Development of a pharmacokinetic/pharmacodynamic/disease progression model in NC/Nga mice for development of novel anti-atopic dermatitis drugs.
Baek, IH; Chae, JW; Kang, W; Kwon, KI; Lee, BY; Song, GY, 2014
)
0.4
" To test this hypothesis and address a key question for human translatability of animal model studies of D and DA or AGN extract, we conducted a single oral dose human pharmacokinetic study of D and DA delivered through an AGN-based dietary supplement Cogni."( Single oral dose pharmacokinetics of decursin and decursinol angelate in healthy adult men and women.
Chee, W; Hale, TW; Jiang, C; Li, L; Lü, J; Xing, C; Zhang, J, 2015
)
0.69

Bioavailability

The extremely low bioavailability of decursin after its administration via the hepatic portal vein (the fraction of dose escaping first-pass elimination in the liver, FH = 0.0%) was studied. Following oral administration, decursInol exhibited high oral bioavailability (>45%) and rapid absorption (T(max), 0.5%).

ExcerptReferenceRelevance
" In the current study, we compared for the first time the plasma profiles of decursinol, when equal moles of decursin/decursinol angelate or decursinol were given to rats by oral gavage, and investigated the effect of different formulas and other chemicals in Angelica gigas extract on the bioavailability of decursinol."( Single oral dose pharmacokinetics of decursin, decursinol angelate, and decursinol in rats.
Kim, SH; Li, L; Lü, J; Xing, C; Zhang, J, 2013
)
0.89

Dosage Studied

Diketone decursin, epoxide decurs in and oxim Decursin might be formulated into an oral dosage form (log P: 0-3) by an automatic titration analysis. Measurement of plasma decursInol concentration, at 3[Formula: see text]h after the last dose of respective dosing regimen, showed higher circulating level in the decursins-treated NSG mice than in the D/DA-treated mice.

ExcerptRelevanceReference
" Diketone decursin, epoxide decursin and oxim decursin might be formulated into an oral dosage form (log P: 0-3) by an automatic titration analysis."( Physicochemical characterization and toxicity of decursin and their derivatives from Angelica gigas.
Baek, IH; Chae, JW; Cho, SK; Kwon, KI; Mahat, B; Song, GY; Song, JS, 2012
)
1.04
" Finally, these results may be useful for the design of dosage regimens of decursin and its derivatives."( Biopharmaceutical characterization of decursin and their derivatives for drug discovery.
Baek, IH; Chae, JW; Kwon, KI; Ma, JY; Mahat, B; Song, GY; Song, JS, 2013
)
0.89
" Measurement of plasma decursinol concentration, at 3[Formula: see text]h after the last dose of respective dosing regimen, showed higher circulating level in the decursinol-treated NSG mice than in the D/DA-treated mice."( Prostate Cancer Xenograft Inhibitory Activity and Pharmacokinetics of Decursinol, a Metabolite of Angelica gigas Pyranocoumarins, in Mouse Models.
Cooper, TK; Jiang, C; Lü, J; Puppala, M; Tang, SN; Wu, W; Xing, C; Zhang, Y, 2017
)
1
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
coumarins
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (3)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Amine oxidase [flavin-containing] AHomo sapiens (human)IC50 (µMol)1.76000.00002.37899.7700AID1373671; AID1498697; AID1624343
AcetylcholinesteraseHomo sapiens (human)IC50 (µMol)390.00000.00000.933210.0000AID360659
Beta-secretase 1Homo sapiens (human)IC50 (µMol)500.00000.00061.619410.0000AID637774
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (33)

Processvia Protein(s)Taxonomy
biogenic amine metabolic processAmine oxidase [flavin-containing] AHomo sapiens (human)
positive regulation of signal transductionAmine oxidase [flavin-containing] AHomo sapiens (human)
dopamine catabolic processAmine oxidase [flavin-containing] AHomo sapiens (human)
acetylcholine catabolic process in synaptic cleftAcetylcholinesteraseHomo sapiens (human)
regulation of receptor recyclingAcetylcholinesteraseHomo sapiens (human)
osteoblast developmentAcetylcholinesteraseHomo sapiens (human)
acetylcholine catabolic processAcetylcholinesteraseHomo sapiens (human)
cell adhesionAcetylcholinesteraseHomo sapiens (human)
nervous system developmentAcetylcholinesteraseHomo sapiens (human)
synapse assemblyAcetylcholinesteraseHomo sapiens (human)
receptor internalizationAcetylcholinesteraseHomo sapiens (human)
negative regulation of synaptic transmission, cholinergicAcetylcholinesteraseHomo sapiens (human)
amyloid precursor protein metabolic processAcetylcholinesteraseHomo sapiens (human)
positive regulation of protein secretionAcetylcholinesteraseHomo sapiens (human)
retina development in camera-type eyeAcetylcholinesteraseHomo sapiens (human)
acetylcholine receptor signaling pathwayAcetylcholinesteraseHomo sapiens (human)
positive regulation of cold-induced thermogenesisAcetylcholinesteraseHomo sapiens (human)
proteolysisBeta-secretase 1Homo sapiens (human)
membrane protein ectodomain proteolysisBeta-secretase 1Homo sapiens (human)
response to lead ionBeta-secretase 1Homo sapiens (human)
protein processingBeta-secretase 1Homo sapiens (human)
amyloid-beta formationBeta-secretase 1Homo sapiens (human)
amyloid precursor protein catabolic processBeta-secretase 1Homo sapiens (human)
positive regulation of neuron apoptotic processBeta-secretase 1Homo sapiens (human)
amyloid-beta metabolic processBeta-secretase 1Homo sapiens (human)
detection of mechanical stimulus involved in sensory perception of painBeta-secretase 1Homo sapiens (human)
prepulse inhibitionBeta-secretase 1Homo sapiens (human)
cellular response to copper ionBeta-secretase 1Homo sapiens (human)
cellular response to manganese ionBeta-secretase 1Homo sapiens (human)
presynaptic modulation of chemical synaptic transmissionBeta-secretase 1Homo sapiens (human)
signaling receptor ligand precursor processingBeta-secretase 1Homo sapiens (human)
cellular response to amyloid-betaBeta-secretase 1Homo sapiens (human)
amyloid fibril formationBeta-secretase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (20)

Processvia Protein(s)Taxonomy
protein bindingAmine oxidase [flavin-containing] AHomo sapiens (human)
primary amine oxidase activityAmine oxidase [flavin-containing] AHomo sapiens (human)
aliphatic amine oxidase activityAmine oxidase [flavin-containing] AHomo sapiens (human)
monoamine oxidase activityAmine oxidase [flavin-containing] AHomo sapiens (human)
flavin adenine dinucleotide bindingAmine oxidase [flavin-containing] AHomo sapiens (human)
amyloid-beta bindingAcetylcholinesteraseHomo sapiens (human)
acetylcholinesterase activityAcetylcholinesteraseHomo sapiens (human)
cholinesterase activityAcetylcholinesteraseHomo sapiens (human)
protein bindingAcetylcholinesteraseHomo sapiens (human)
collagen bindingAcetylcholinesteraseHomo sapiens (human)
hydrolase activityAcetylcholinesteraseHomo sapiens (human)
serine hydrolase activityAcetylcholinesteraseHomo sapiens (human)
acetylcholine bindingAcetylcholinesteraseHomo sapiens (human)
protein homodimerization activityAcetylcholinesteraseHomo sapiens (human)
laminin bindingAcetylcholinesteraseHomo sapiens (human)
amyloid-beta bindingBeta-secretase 1Homo sapiens (human)
endopeptidase activityBeta-secretase 1Homo sapiens (human)
aspartic-type endopeptidase activityBeta-secretase 1Homo sapiens (human)
protein bindingBeta-secretase 1Homo sapiens (human)
peptidase activityBeta-secretase 1Homo sapiens (human)
beta-aspartyl-peptidase activityBeta-secretase 1Homo sapiens (human)
enzyme bindingBeta-secretase 1Homo sapiens (human)
protein serine/threonine kinase bindingBeta-secretase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (32)

Processvia Protein(s)Taxonomy
mitochondrionAmine oxidase [flavin-containing] AHomo sapiens (human)
mitochondrial outer membraneAmine oxidase [flavin-containing] AHomo sapiens (human)
cytosolAmine oxidase [flavin-containing] AHomo sapiens (human)
mitochondrionAmine oxidase [flavin-containing] AHomo sapiens (human)
extracellular regionAcetylcholinesteraseHomo sapiens (human)
basement membraneAcetylcholinesteraseHomo sapiens (human)
extracellular spaceAcetylcholinesteraseHomo sapiens (human)
nucleusAcetylcholinesteraseHomo sapiens (human)
Golgi apparatusAcetylcholinesteraseHomo sapiens (human)
plasma membraneAcetylcholinesteraseHomo sapiens (human)
cell surfaceAcetylcholinesteraseHomo sapiens (human)
membraneAcetylcholinesteraseHomo sapiens (human)
neuromuscular junctionAcetylcholinesteraseHomo sapiens (human)
synaptic cleftAcetylcholinesteraseHomo sapiens (human)
synapseAcetylcholinesteraseHomo sapiens (human)
perinuclear region of cytoplasmAcetylcholinesteraseHomo sapiens (human)
side of membraneAcetylcholinesteraseHomo sapiens (human)
lysosomeBeta-secretase 1Homo sapiens (human)
endosomeBeta-secretase 1Homo sapiens (human)
early endosomeBeta-secretase 1Homo sapiens (human)
late endosomeBeta-secretase 1Homo sapiens (human)
multivesicular bodyBeta-secretase 1Homo sapiens (human)
endoplasmic reticulum lumenBeta-secretase 1Homo sapiens (human)
Golgi apparatusBeta-secretase 1Homo sapiens (human)
trans-Golgi networkBeta-secretase 1Homo sapiens (human)
plasma membraneBeta-secretase 1Homo sapiens (human)
synaptic vesicleBeta-secretase 1Homo sapiens (human)
cell surfaceBeta-secretase 1Homo sapiens (human)
endosome membraneBeta-secretase 1Homo sapiens (human)
membraneBeta-secretase 1Homo sapiens (human)
axonBeta-secretase 1Homo sapiens (human)
dendriteBeta-secretase 1Homo sapiens (human)
neuronal cell bodyBeta-secretase 1Homo sapiens (human)
membrane raftBeta-secretase 1Homo sapiens (human)
recycling endosomeBeta-secretase 1Homo sapiens (human)
Golgi-associated vesicle lumenBeta-secretase 1Homo sapiens (human)
hippocampal mossy fiber to CA3 synapseBeta-secretase 1Homo sapiens (human)
endosomeBeta-secretase 1Homo sapiens (human)
plasma membraneBeta-secretase 1Homo sapiens (human)
trans-Golgi networkBeta-secretase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (22)

Assay IDTitleYearJournalArticle
AID1313594Inhibition of Wnt/beta-catenin pathway in human HEK293 cells at 20 uM after 15 hrs by TOPflash dual luciferase reporter gene assay2016Bioorganic & medicinal chemistry letters, 08-01, Volume: 26, Issue:15
Synthesis and evaluation of (+)-decursin derivatives as inhibitors of the Wnt/β-catenin pathway.
AID426214Cytotoxicity against human KB cells upto 50 uM by neutral red assay2009Journal of natural products, Jun, Volume: 72, Issue:6
Scuteflorins A and B, dihydropyranocoumarins from Scutellaria lateriflora.
AID376761Neuroprotective effect against glutamate-stimulated rat cortical cells assessed as cell viability at 10 uM after 1 hr by LDH assay relative to control2005Journal of natural products, Jan, Volume: 68, Issue:1
Four new neuroprotective dihydropyranocoumarins from Angelica gigas.
AID426210Cytotoxicity against human SW1353 cells by neutral red assay2009Journal of natural products, Jun, Volume: 72, Issue:6
Scuteflorins A and B, dihydropyranocoumarins from Scutellaria lateriflora.
AID1624343Inhibition of human recombinant MAO-A using kynuramine as substrate after 10 mins2019Bioorganic & medicinal chemistry letters, 03-15, Volume: 29, Issue:6
Osthenol, a prenylated coumarin, as a monoamine oxidase A inhibitor with high selectivity.
AID1498697Inhibition of recombinant human MAO-A using kynuramine as substrate incubated for 10 mins by spectrophotometric method2018Bioorganic & medicinal chemistry letters, 08-01, Volume: 28, Issue:14
Selective inhibition of monoamine oxidase A by chelerythrine, an isoquinoline alkaloid.
AID548093Cytotoxicity against mouse B16F10 cells assessed as cell viability after 24 hrs by MTT assay2010European journal of medicinal chemistry, Dec, Volume: 45, Issue:12
Synthesis of (S)-(+)-decursin and its analogues as potent inhibitors of melanin formation in B16 murine melanoma cells.
AID426208Cytotoxicity against pig LLC-PK11 cells upto 50 uM by neutral red assay2009Journal of natural products, Jun, Volume: 72, Issue:6
Scuteflorins A and B, dihydropyranocoumarins from Scutellaria lateriflora.
AID637775Inhibition of recombinant human BACE1 using Rh-EVNLDAEFK as substrate at 500 uM after 60 mins by fluorescence quenching assay2012Bioorganic & medicinal chemistry, Jan-15, Volume: 20, Issue:2
Structure-activity relationships for naturally occurring coumarins as β-secretase inhibitor.
AID426211Inhibition of SP1-dependent luciferase expression2009Journal of natural products, Jun, Volume: 72, Issue:6
Scuteflorins A and B, dihydropyranocoumarins from Scutellaria lateriflora.
AID426207Cytotoxicity against african green monkey Vero cells upto 50 uM by neutral red assay2009Journal of natural products, Jun, Volume: 72, Issue:6
Scuteflorins A and B, dihydropyranocoumarins from Scutellaria lateriflora.
AID426216Cytotoxicity against human SKOV3 cells upto 50 uM by neutral red assay2009Journal of natural products, Jun, Volume: 72, Issue:6
Scuteflorins A and B, dihydropyranocoumarins from Scutellaria lateriflora.
AID1313602Inhibition of Wnt/beta-catenin pathway in human HEK293 cells after 15 hrs by TOPflash dual luciferase reporter gene assay2016Bioorganic & medicinal chemistry letters, 08-01, Volume: 26, Issue:15
Synthesis and evaluation of (+)-decursin derivatives as inhibitors of the Wnt/β-catenin pathway.
AID1373671Inhibition of human recombinant MAOA using kynuramine as substrate preincubated for 30 mins followed by substrate addition2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Selective inhibition of monoamine oxidase A by hispidol.
AID426212Cytotoxicity against human HepG2 cells upto 50 uM by neutral red assay2009Journal of natural products, Jun, Volume: 72, Issue:6
Scuteflorins A and B, dihydropyranocoumarins from Scutellaria lateriflora.
AID360659Inhibition of AChE by spectrophotometry2001Journal of natural products, May, Volume: 64, Issue:5
Coumarins isolated from Angelica gigas inhibit acetylcholinesterase: structure-activity relationships.
AID548092Inhibition of melanin production in mouse B16F10 cells at 100 uM after 2 days2010European journal of medicinal chemistry, Dec, Volume: 45, Issue:12
Synthesis of (S)-(+)-decursin and its analogues as potent inhibitors of melanin formation in B16 murine melanoma cells.
AID376759Neuroprotective effect against glutamate-stimulated rat cortical cells assessed as cell viability at 0.1 uM after 1 hr by LDH assay relative to control2005Journal of natural products, Jan, Volume: 68, Issue:1
Four new neuroprotective dihydropyranocoumarins from Angelica gigas.
AID637774Inhibition of recombinant human BACE1 using Rh-EVNLDAEFK as substrate after 60 mins by fluorescence quenching assay2012Bioorganic & medicinal chemistry, Jan-15, Volume: 20, Issue:2
Structure-activity relationships for naturally occurring coumarins as β-secretase inhibitor.
AID426213Cytotoxicity against human SK-MEL cells upto 50 uM by neutral red assay2009Journal of natural products, Jun, Volume: 72, Issue:6
Scuteflorins A and B, dihydropyranocoumarins from Scutellaria lateriflora.
AID376760Neuroprotective effect against glutamate-stimulated rat cortical cells assessed as cell viability at 1 uM after 1 hr by LDH assay relative to control2005Journal of natural products, Jan, Volume: 68, Issue:1
Four new neuroprotective dihydropyranocoumarins from Angelica gigas.
AID426215Cytotoxicity against human BT549 cells upto 50 uM by neutral red assay2009Journal of natural products, Jun, Volume: 72, Issue:6
Scuteflorins A and B, dihydropyranocoumarins from Scutellaria lateriflora.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (138)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's2 (1.45)18.2507
2000's37 (26.81)29.6817
2010's75 (54.35)24.3611
2020's24 (17.39)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 32.19

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index32.19 (24.57)
Research Supply Index4.95 (2.92)
Research Growth Index6.09 (4.65)
Search Engine Demand Index42.09 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (32.19)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (0.72%)5.53%
Reviews3 (2.16%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other135 (97.12%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]